PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
11489444-0	2001	Thiopental inhibits NF-kappaB activation in human glioma cells and experimental brain inflammation.	Thiopental	0-10	nuclear factor kappa B subunit 1	Homo sapiens	20-29	
12883408-2	2003	The authors have recently reported that thiopental inhibits activation of nuclear factor (NF) kappaB, a transcription factor implicated in the expression of many inflammatory genes.	Thiopental	40-50	nuclear factor kappa B subunit 1	Homo sapiens	74-100	
12883408-5	2003	In addition, they investigated the direct effect of thiopental on activated NF-kappaB DNA binding activity.	Thiopental	52-62	nuclear factor kappa B subunit 1	Homo sapiens	76-85	
12883408-15	2003	CONCLUSION: Thiopental-mediated inhibition of NF-kappaB activation is due to the suppression of IkappaB kinase activity and depends at least in part on the thio-group of the barbiturate molecule.	Thiopental	12-22	nuclear factor kappa B subunit 1	Homo sapiens	46-55	
11981162-5	2002	RESULTS: Thiopental inhibited the activation of the transcription factor NF-kappaB but did not alter the activity of the cyclic adenosine monophosphate response element binding protein.	Thiopental	9-19	nuclear factor kappa B subunit 1	Homo sapiens	73-82	
11981162-7	2002	Thiopental-mediated suppression of NF-kappaB could be observed in Jurkat cells and in primary CD3+ lymphocytes from healthy volunteers, was time- and concentration-dependent, occurred at concentrations that are clinically achieved, and persisted for hours after the incubation.	Thiopental	0-10	nuclear factor kappa B subunit 1	Homo sapiens	35-44	
11981162-10	2002	CONCLUSION: The results demonstrate that thiopental inhibits the activation of NF-kappaB and may thus provide a molecular mechanism for some of the immunosuppressing effects associated with thiopental therapy.	Thiopental	41-51	nuclear factor kappa B subunit 1	Homo sapiens	79-88	
11981162-10	2002	CONCLUSION: The results demonstrate that thiopental inhibits the activation of NF-kappaB and may thus provide a molecular mechanism for some of the immunosuppressing effects associated with thiopental therapy.	Thiopental	190-200	nuclear factor kappa B subunit 1	Homo sapiens	79-88	
17592348-2	2007	This study was designed to quantitatively evaluate the neuroprotective effects of thiopental, propofol, and halothane on brain ischemia by determining P50, ischemic time necessary for causing 50% neuronal damage.	Thiopental	82-92	nuclear factor kappa B subunit 1	Homo sapiens	151-154	
17592348-6	2007	P50 in the thiopental, propofol, and halothane groups were estimated to be 8.4, 6.5 (P<0.05, vs. thiopental), and 5.1 (P<0.05) minutes, respectively.	Thiopental	11-21	nuclear factor kappa B subunit 1	Homo sapiens	0-3	
17592348-6	2007	P50 in the thiopental, propofol, and halothane groups were estimated to be 8.4, 6.5 (P<0.05, vs. thiopental), and 5.1 (P<0.05) minutes, respectively.	Thiopental	100-110	nuclear factor kappa B subunit 1	Homo sapiens	0-3	
17592348-10	2007	By using P50, we found that the neuroprotective effect of thiopental was greater than that of propofol.	Thiopental	58-68	nuclear factor kappa B subunit 1	Homo sapiens	9-12	
11489444-6	2001	Electrophoretic mobility shift assays demonstrated that thiopental inhibited NF-kappaB activation induced by LPS in A-172 cells.	Thiopental	56-66	nuclear factor kappa B subunit 1	Homo sapiens	77-86